

## Corporate Profile



# Protecting Lives for the Future

The spread of invisible bacteria and viruses inhibits lively activities of people and societies around the world. We have faced and will continue to face such threats. Meiji Seika Pharma has been tackling the threat of infectious disease to protect the general public. We have been providing antibacterial drugs for more than 70 years, and we continue to tackle the challenge of using vaccines to protect against infectious diseases, ensuring a sustainable supply of antibacterial drugs, and developing effective antibacterial drugs against drug-resistant bacteria.

## Group Slogan

Now ideas for wellness  
**meiji**

The Meiji Group will embody good ideas that everyone can appreciate in the field of wellness. Being healthy in mind and body makes us happy, and smiling is contagious, as people envisage a brighter future on a healthy planet. Now we need ideas for wellness.

## TOP MESSAGE

**As a leading supplier of vaccines and solutions for infectious diseases, we continue to advance as a company dedicated to addressing social issues.**

As a leading supplier of vaccines and solutions for infectious diseases, we offer a comprehensive lineup for both prevention and treatment. We work tirelessly to address public health-related social issues, including combating emerging and re-emerging infectious diseases, addressing antimicrobial resistance (AMR), and ensuring a stable supply of pharmaceuticals.

In particular, we aim to domestically manufacture the active pharmaceutical ingredients (APIs) for penicillin-based antibiotics, which have been designated as specified critical products. This initiative will ensure an uninterrupted supply to healthcare facilities, even if imports are disrupted.

We also aim to enhance our managerial foundation by promoting the development of innovative vaccines and antibiotics through the synergistic strengths of Meiji Group's pharmaceutical segments. This goal will be achieved by accelerating the managerial integration of Meiji Seika Pharma and KM Biologics.

In terms of overseas expansion, we will strengthen our company's quality through such activities, achieving sustainable and steady growth in the process.

Infectious diseases will always pose a threat to our health. Reflecting the sentiment of our company's tagline, "Protecting Lives for the Future," we will pursue progressive initiatives to safeguard the health and well-being of the public.

Meiji Seika Pharma Co., Ltd.  
**Daikichiro Kobayasahi** Chairman and Representative Director  
**Toshiaki Nagasato** President and Representative Director





## Why take on the challenge of infectious diseases?



## PURPOSE

### We have been providing antibacterial drugs for over 70 years.

The Meiji Group began manufacturing penicillin in 1946. At that time, the Meiji Group, which was involved in food and dairy products, was very familiar with lactose—one of the essential raw materials for penicillin. Since the start of penicillin sales, we have expanded our lineup to become a leading supplier in systemic antibacterial drugs with a wide-ranging product.



### Our goal is to protect Japanese healthcare with antibacterial drugs.

Four beta-lactam antibiotics, which are essential for the treatment of infections and prevention of surgical infections, have been designated by government ordinance as Specified Critical Products. Currently, the active pharmaceutical ingredients (APIs or bulk drugs) for many antibacterial drugs, including those used for beta-lactam antibiotics, are highly dependent on imports from abroad. Meiji Seika Pharma, as the top supplier of two out of the above four drugs, is advancing domestic production, from APIs to finished products, to ensure a stable supply in Japan.




### Start of manufacturing penicillin APIs in Japan

Antibacterial drugs have sometimes experienced shortages in recent times due to unstable procurement of raw materials, leading to a growing sense of crisis among medical professionals. In order to resolve concerns related to supply, Meiji Seika Pharma applied to join the Ministry of Health, Labor and Welfare's "Program for Supporting Stable Supply of Pharmaceuticals." Upon acceptance, we began to manufacture the active pharmaceutical ingredient (API) of penicillin for the first time in about 30 years at our Gifu Plant.



### Desire to eliminate drug-resistant bacteria

Antimicrobial Resistance (AMR), against which antibacterial drugs lack efficacy, has recently become an issue, becoming ever more prevalent worldwide. It has been estimated that fatalities will total 10 million by 2050 unless effective countermeasures are taken. Meiji Seika Pharma has been promoting the development of antibacterial drugs that are effective on otherwise drug-resistant bacteria.







## How do we tackle infectious diseases?


# BUSINESS

## Tackling infectious diseases from the dual perspectives of prevention and treatment.

In 2018, KM Biologics joined the Meiji Group, and began to provide various vaccines. We focus on the stable supply of vaccines and the development of new vaccines, and strive to contribute to public health from the dual perspectives of prevention and treatment of infectious diseases.

## Optimized R&D through open innovation

The seeds of innovative new drugs derived through academia have recently increased. We have been optimizing our internal research system, promoting open innovation-type joint research with academia, and strive to form tie-ups with startups. We are beginning to see the results of such integration of human resources from both within and outside the company.



## Business area

### Antibacterial drugs (Infectious diseases)

We have established ourselves as a leading company in the provision of systemic antibacterial drugs by building up a varied product line. As we hold over 50% of the market share in Japan, by establishing a value chain system from development to production in Japan, we will ensure a stable supply of injectable penicillin-based antibacterial drugs.




### Vaccines (Infectious diseases)

We sell vaccines to inoculate against COVID-19, influenza, and DTaP-IPV-Hib, a pentavalent (five-in-one) combination vaccine. While striving to acquire new vaccine technologies, such as mRNA, they are also working to develop technology for inactivated vaccines, that have long been used in Japan.



### CNS disorders

We offer an extensive lineup of therapeutic drugs, such as Japan's first noradrenergic and specific serotonergic antidepressant (NaSSA), REFLEX; an antipsychotic drug, SYCREST, for depression and integration disorder syndrome, and we strive to provide appropriate information via specialized MRs.



### Immunoinflammatory area

We also focus on hematological oncology areas, which are closely related to infectious diseases. In the area of hematology, there remain diseases with limited treatment options. We will continuously strive to improve the QOL and prognosis of patients who suffer from hematological cancers by expanding the range of products under development to address unmet medical needs.



### Generic drugs

The Company has been involved in the generic drug business ahead of its competitors as a manufacturer of new drugs. Furthermore, generic drugs are being manufactured by Medreich Ltd. in India, which joined our group in 2015. The highest quality Japanese standards are realized at low cost thanks to strict quality management.



### Contract Manufacturing Organization (CMO) / Contract Development and Manufacturing Organization (CDMO)

Medreich Ltd., which boasts extensive CMO/CDMO success and mass production facilities, is always looking to expand trade with existing clients, such as global pharmaceutical companies, and attract new business. In Japan, Meiji Seika Pharmatech also handles the manufacturing of oral solid preparations under contract.



# GLOBAL

**Accelerating business development worldwide,  
including the Asian market,  
where further growth is expected.**



We started to export antibacterial drugs in around 1950, and prepared a global production system and sales network based on local subsidiaries, such as in Indonesia, Thailand, China, Spain, and India. Medreich Ltd. (India), which has mass production facilities, joined our group, so we can now meet the expanding international demand for contract manufacturing of pharmaceutical products.

## Production system

From the procurement of bulk drugs and raw materials to manufacturing, packaging, and shipping, production is carried out under a strict GMP\*-based quality control system. The overall supply chain is centrally managed, and a system that ensures stable supply has been prepared. Reliable quality products are delivered to the medical frontlines thanks to advanced manufacturing facilities, strict production control, and all employees retain exceptional awareness of the need for quality.

\*GMP: Good Manufacturing Practices



## Reliability and quality assurance

Earning the trust of patients and healthcare professionals alike, while contributing to society, is adopted as our basic policy to guarantee reliability. In order to do that, we ensure and improve reliability by establishing and operating a quality management system. Reassuring products are delivered by collecting information on manufacturing and quality control, including raw material procurement, and promoting reliability assurance activities to provide information for proper use.



# SUSTAINABILITY


**Designing a future in which the whole world is  
happy and healthy.**

## Meiji Group Sustainability 2026 Vision

Meiji Group created three themes under which to promote our measures, namely, "Healthier Lives," "Caring for the Earth," and "Thriving Communities," plus a shared theme, "Sustainable Sourcing;" and set out to identify and define material issues and Key Performance Indicators (KPIs), and promote specific activities while addressing social issues.



For further details



## Coronavirus countermeasures

Since May 2020, we have been utilizing our extensive vaccine development-related knowhow in collaboration with national research institutes\* to develop an inactivated vaccine (KD-414) to protect against the novel coronavirus infection (COVID-19). We also acquired approval for the manufacturing and sales in Japan of a next-generation mRNA vaccine (Replicon vaccine), KOSTAIVE, as an intramuscular injection, in November 2023, and have been supplying these vaccines since the autumn of 2024.



## Stable supply of antibacterial drugs

In order to realize a stable supply of 6-APA, a common intermediate for penicillin antibacterial drugs that currently depends on imports, preparations are advanced for production at our Gifu Plant. We will make every effort to strengthen our stable supply system to fulfill our social responsibility by taking a core role in the treatment of infectious diseases.





# HISTORY

# OUTLINE

1916-

## Foundation

1916

Tokyo Confectionery Co., Ltd. (Tokyo Confectionery), the predecessor of Meiji Seika, is established.

1924

Tokyo Confectionery changes its name to Meiji Seika Kaisha, Ltd. (Meiji Seika).

1946-

## Full-scale entry into pharmaceutical business

1946

The pharmaceutical business is launched with the commencement of penicillin production.

Due to a pharmaceuticals shortage across the country, the company began cultivating penicillin in "fruit syrup" bottles using lactose as a raw material. This marked the company's entry into the pharmaceutical business.



1974-

## Start of expansion into overseas business

1974

P.T. Meiji Indonesian Pharmaceutical Industries is established as an overseas group company.

1989

The antianxiety drug *MEILAX* is launched.

The antianxiety drug *MEILAX* is developed under a technological license from Sanofi in France. This became the precursor to our foray into central nervous system (CNS) disorders.

1994

The antibiotic *MEIACT* is launched.

With increasing needs for new antibiotics against emerging bacterial strains, *MEIACT*, an in-house developed antibiotic, was launched. This drug formulation remains in widespread use, particularly for pediatrics.



1998-

## Diversification of therapeutic areas

1998

Started full operation of the generic drugs business.

As a R&D-oriented pharmaceutical company, we were industry leaders in terms of entering the domain of generic drugs, which drew attention from the perspective of reducing the burden on patients.

1999

The antidepressant drug *DEPROMEL*, the first SSRI in Japan, is launched.

2004

The drug for Photodynamic Therapy (PDT) *LASERPHYRIN* is launched.

2011-

## Seeking more health value

2011

Meiji Seika Pharma Co., Ltd. begins operation to succeed the pharmaceutical business of the former Meiji Seika Kaisha Ltd, following a reorganization of companies within the Meiji Group.

2015

Medreich Ltd. (India) joins the Group.

With the advent of a super-aged society and a rapidly growing need for generic drugs in Japan, we subsidized Medreich Ltd. Under the umbrella of Medreich, which has a number of production sites in India, and has been expanding its sales network internationally, we are laying the groundwork for a stable supply system for domestic use, while also striving to expand operations globally.

2016

Establishment of Me Pharma, a subsidiary manufacturing and selling generic drugs

2018

KM Biologics Co., Ltd., which conducts research, development, and manufacturing of biological drugs (vaccines, etc.), joins the Group.

KM Biologics became a member of the Meiji Group, and took over the main business of the Chemo-Sero-Therapeutic Research Institute. Currently, KM Biologics and Meiji Seika Pharma operate in an integrated manner, in terms of R&D and sales of vaccines.

2022

Meiji Seika Pharmatech Co., Ltd., taking over the formulation manufacturing function of the Odawara Factory, is established.

2024

Five-in-one combination vaccine *QUINTOVAC* is launched.

A selective ROCK2 Inhibitor for the treatment of chronic graft-versus-host disease (cGVHD), *REZUROCK* is launched.

A self-amplifying mRNA vaccine against COVID-19, *KOSTAIVE* is launched.



## Meiji Seika Pharma Co., Ltd.

Established: October 9, 1916

President and Representative Director: Toshiaki Nagasato

Number of Employees: 5,683 (As of March 31, 2025)

Main Businesses: Manufacturing and sale of ethical pharmaceuticals, agricultural chemicals and veterinary drugs

Capital: ¥28.363 billion

Head Office: 4-16 Kyobashi 2-chome, Chuo-ku, Tokyo, Japan

## Operating Bases and Group Companies

### Japan

#### Head office

#### Branches

Pharmaceuticals Hokkaido Branch / Pharmaceuticals Tohoku Branch / Pharmaceuticals Tokyo Branch / Pharmaceuticals Kanto Branch / Pharmaceuticals Chubu Branch / Pharmaceuticals Kansai Branch / Pharmaceuticals Chugoku & Shikoku Branch / Pharmaceuticals Kyushu Branch

#### Research Laboratories

Pharmaceuticals Research Center

#### Plants

Gifu Plant

#### Group Companies

Meiji Seika Pharmatech Co., Ltd. / Me Pharma Co., Ltd. / OHKURA Pharmaceutical Co., Ltd. / Romeck Pharma, LLC / MIYAKO YUSO TRANSPORTATION CO., LTD.

### Overseas

#### Group Companies

Taiwan Meiji Pharma Co., Ltd. / Guangdong Meiji Pharmaceutical Co., Ltd. / PT. Meiji Indonesian Pharmaceutical Industries / Thai Meiji Pharmaceutical Co., Ltd. / Medreich Limited / Adcock Ingram Limited / Adcock Ingram Pharma Private Limited / Medreich Life care Limited / Medreich plc / Medreich Australia Pty Ltd. / Medreich Far East Limited / Inopharm Limited / Medreich New Zealand Limited / Meiji Pharma Spain, S.A. / Meiji Seika Europe B.V. / Meiji Pharma USA Inc.

## Wellness stories

### Meiji Group stories about its consideration and efforts concerning health values for the public and the world

Introducing various measures concerning health values for the public and the world, such as the development of foods that benefit our health; the development of pharmaceuticals to treat infectious, intractable and rare diseases; and the procurement of sustainable raw materials.



For further details

